Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
19 Results for "
PANC-1 xenograft
" in MedChemExpress (MCE) Product Catalog:
Products (19)
19 Results for "PANC-1 xenograft" in MCE Product Catalog:
Cat. No.: HY-123009
CAS No.: 927823-01-6
Target:
HIF/HIF Prolyl-Hydroxylase Histone Acetyltransferase Apoptosis Carbonic Anhydrase VEGFR GLUT
Research Areas:
KCN1 is a p300/HIF-1α interaction inhibitor with a Kd value of 345 nM for p300-CH1. KCN1 binds to the CH1 domain of p300, blocks the assembly of the p300/HIF-1α complex, and disrupts the HIF-1α-p300/CBP interaction. KCN1 inhibits cancer cell growth, induces cancer cell cycle arrest and apoptosis. KCN1 inhibits β-galactosidase activity and downregulates the expression of VEGF, Glut1, CA9 and CAIX. KCN1 exerts anticancer activity in mouse tumor xenograft models. KCN1 can be used in research related to malignant glioma, pancreatic cancer and metastatic uveal melanoma .
Cat. No.: HY-155020
CAS No.: 2848632-52-8
Research Areas:
Antitumor agent-101 is a selective covalent inhibitor of lysine methyltransferases G9a/GLP, with IC50s of 8.5 nM and 5.5 nM for G9a and GLP, respectively. Antitumor agent-101 shows antitumor efficacy in the PANC-1 xenograft model .
Cat. No.: HY-155991
CAS No.: 2893777-88-1
RUNX-IN-2 (Compound Conjugate 3) covalently binds to the RUNX-binding sequences, and inhibits the binding of RUNX proteins to their target sites. RUNX-IN-2 induces the p53-dependent apoptosis and inhibits cancer cell growth. RUNX-IN-2 inhibits tumor growth in PANC-1 xenograft mice. RUNX-IN-2 has high alkylation efficiency and specificity .
Cat. No.: HY-169830
CAS No.: 3033734-59-4
Target:
Research Areas:
2-(Cyclohexylmethyl)-plumbagin is a derivative of the naphthoquinone compound Plumbagin (HY-N1497). Under nutrient-deprived conditions, 2-(Cyclohexylmethyl)-plumbagin selectively exhibits cytotoxicity against PANC-1 human pancreatic cancer cells (PC50 = 0.11 µM) and reduces the phosphorylation of Akt and mTOR in PANC-1 cells. 2-(Cyclohexylmethyl)-plumbagin also induces apoptosis (Apoptosis) in PANC-1 cells at a concentration of 1 µM. Additionally, 2-(Cyclohexylmethyl)-plumbagin reduces tumor volume and weight in a xenograft MiaPaCa-2 pancreatic cancer mouse model .
0 Images
RNA,(5'-GGGCGfUGfCfUGGGfCfCfUGfUAAAfUAfCAfCGfCAfUfCGfUAfUfCfUfCGAfUfUfCGfCAfUfCfCfCfUGAfCfUfCAfUAAfCfCfCAGAGGfUfCGAfUG-3') sodium salt, (All C and U are 2'-fluoro-pyrimidine modified nucleic acids.)
Cat. No.: HY-164185
Cat. No.: HY-158726
CAS No.: 2480150-28-3
Cat. No.: HY-159577
CAS No.: 2896739-91-4
Nic-15 (compound 4n) is an anti-constrictive agent used to antagonize the hypovascularity of pancreatic tumors. The hypovascularity allows cancer cells to adapt to the nutrient-deficient tumor microenvironment and develop drug resistance. Nic-15 can regulate the PI3K/Akt/mTOR pathway and alleviate ER stress induced by Gemcitabine (HY-17026). Nic-15 can significantly inhibit the migration and colony formation of MIA PaCa-2 and PANC-1 pancreatic cancer cells. The combination of Nic-15 and Gemcitabine can effectively solve the problem of pancreatic tumor resistance. In an in vivo xenograft model, Nic-15 can significantly enhance the efficacy of Gemcitabine .
Cat. No.: HY-149092
CAS No.: 2097497-16-8
Target:
Research Areas:
Anticancer agent 109 (compound 6-15) is an inhibitor of the Gas6-Axl axis with anti-cancer activity. Anticancer agent 109 inhibits the expression of Gas6 and Axl, and the expression p-PI3K and p-AKT in cancer cells, leads to G1 phase arrest and promotes cancer cells apoptosis, and inhibits tumor growth significantly in nude mouse tumor bearing models .
Cat. No.: HY-168919
KRASG12C IN-16 (Compound SK-17) is a selective, covalent and an orally active KRAS G12C inhibitor. KRASG12C IN-16 induces Apoptosis. KRASG12C IN-16 effectively prevents the activation of MAPK and PI3K/mTOR signaling pathways. KRASG12C IN-16 displays anti-tumor activity against pancreatic cancer .
Cat. No.: HY-163507
CAS No.: 2725056-38-0
Target:
Research Areas:
ALK5-IN-79 (compound 57) is an ALK inhibitor with anticancer activity, by blocking TGF-β1/SMAD signaling pathway. ALK5-IN-79 attenuates the production of extracellular matrix (ECM) and deposition of collagen. ALK5-IN-79 exhibits adequate pharmacokinetic (PK) properties and good in vivo tolerance.
Cat. No.: HY-12440
CAS No.: 1363145-46-3
HM90822 is an orally active IAP antagonist. HM90822 induces ubiquitination and proteasome-dependent degradation of XIAP, cIAP1 and cIAP2 in sensitive pancreatic cancer cells. HM90822 induces Apoptotic cell death. HM90822 inhibits tumor growth in Panc-1 pancreatic cancer xenograft and orthotopic mouse models. HM90822 can be used for the research of pancreatic cancer .
Cat. No.: HY-P11935
CAS No.: 2410535-57-6
Target:
Wnt Apoptosis Pyroptosis NOD-like Receptor (NLR) Caspase Bcl-2 Family β-catenin GSK-3 Interleukin Related
Research Areas:
Cat. No.: HY-183791A
CAS No.: 2243423-32-5
Target:
Ferroptosis Apoptosis Glutathione Peroxidase ACSL Family Reactive Oxygen Species (ROS) Mitochondrial Metabolism Caspase Bcl-2 Family
Research Areas:
Ferroptosis/apoptosis inducer-5 is an orally active inducer of Ferroptosis and Apoptosis. Ferroptosis/apoptosis inducer-5 downregulates GPX4, upregulates ACSL4, promotes ROS production, activates the Caspase cascade, induces Mitochondrial dysfunction, and alters the Bcl-2/Bax balance. Ferroptosis/apoptosis inducer-5 significantly inhibits tumor growth in a pancreatic cancer xenograft mouse model. Ferroptosis/apoptosis inducer-5 can be used for the research of pancreatic cancer .
Cat. No.: HY-189278
KRAS-IN-64 is a KRAS inhibitor that inhibits KRAS translation by binding to and stabilizing the G-quadruplex in the 5'-UTR of KRAS mRNA, exhibits antiproliferative activity in KRAS-mutant cancer cells, and induces cell cycle arrest, non-apoptotic cell death, and PARP cleavage-mediated apoptosis (apoptosis). KRAS-IN-64 can be used for research on pancreatic cancer .
Cat. No.: HY-189234
Target:
Research Areas:
SAIT-PDZ-5179 is a small-molecule inhibitor of GIPC1 that directly binds to the PDZ domain of GIPC1 with a KD of 943 nM. SAIT-PDZ-5179 reduces the levels of GIPC1-associated signaling proteins and cell viability in pancreatic ductal adenocarcinoma models. SAIT-PDZ-5179 is used for studies on the GIPC1 signaling pathway and pancreatic ductal adenocarcinoma .
Cat. No.: HY-P11901
KH-1 is a KRAS G12D/HDAC2 dual-target inhibitor with Kd values of 11.63 nM and 20.17 nM, respectively. KH-1 induces pancreatic cell apoptosis, cell cycle arrest, and inhibits cell proliferation, invasion and migration, as well as suppresses tumor growth in pancreatic cancer xenograft models. KH-1 can be used for the research of pancreatic cancer .
Cat. No.: HY-180654
CAS No.: 3110272-60-8
Target:
Research Areas:
JWZ-8-103 is an orally active analog of PRLX-93936 (HY-119264) and a molecular glue targeting TRIM21. JWZ-8-103 increases the thermal stability of TRIM21. JWZ-8-103 promotes rapid and efficient interaction between TRIM21 and NUP98 (the apparent EC50 for ternary complex formation with the PRYSPRY domain of TRIM21 and the APD domain of NUP98 is approximately 20 μM), induces extensive ubiquitination and proteasomal degradation of numerous adjacent nucleoporins (NUPs, and thereby triggers cellular apoptosis. JWZ-8-103 can be used for the research of pancreatic cancer .
Cat. No.: HY-180654A
Target:
Research Areas:
JWZ-8-103 hydrochloride is an orally active analog of PRLX-93936 (HY-119264) and a molecular glue targeting TRIM21. JWZ-8-103 hydrochloride increases the thermal stability of TRIM21. JWZ-8-103 hydrochloride promotes rapid and efficient interaction between TRIM21 and NUP98 (the apparent EC50 for ternary complex formation with the PRYSPRY domain of TRIM21 and the APD domain of NUP98 is approximately 20 μM), induces extensive ubiquitination and proteasomal degradation of numerous adjacent nucleoporins (NUPs, and thereby triggers cellular apoptosis. JWZ-8-103 hydrochloride can be used for the research of pancreatic cancer .
- 1
